Vaccine advisors for the US Food and Drug Administration will be meeting on Friday. The meeting will be focused on discussing the application for boosters by Johnson & Johnson.
The J&J administers its initial Covid-19 vaccination through a single shot.
The additional booster dose will be the second dose to the recipients who initially received the Covid-19 vaccine by Johnson & Johnson.
Boosters By J&J Will Be Discussed On Friday By The FDA.
The VRBPAC is all set to study J&J’s application for emergency use authorization for their booster. Johnson & Johnson received its authorization for their initial Covid-19 vaccine way later than Moderna and Pfizer.
The vaccine that Johnson & Johnson provides is different from those by Moderna and Pfizer. The Covid-19 vaccines by Moderna and Pfizer work on mRNA technology, whereas the Covid-19 vaccine by Johnson & Johnson uses an adenovirus.
The virus carries a portion of the coronavirus into the human body so that the body can induce an immune response for the virus.
The J&J vaccine is a single-dose Covid-19 vaccine, but it has been less effective than the other two vaccine shots from the very beginning. Reports suggest that Moderna and Pfizer showed higher efficacy from starting compared to efficacy provided by J&J. Moderna stood with 94 percent efficacy, and Pfizer reflected an efficacy of 95 percent. Apart from these two, Johnson & Johnson had a starting efficacy of 72 percent.
Johnson & Johnson now claims that with boosters at two, six, or eight months, its efficacy can rise to 94 percent. The company says that their studies reveal that the effectiveness provided by their vaccine does not decline as the effectiveness from Pfizer wanes off.
Out of the total American population, about 15 million Americans received the Johnson & Johnson Covid-19 vaccine. Friday’s meeting session will be followed by a voting session. The meeting and voting hours will start at 1:15 p.m. ET and will be two hours approximately.
The Food and Drugs Administration has already given its green flag for emergency use authorization to Pfizer’s booster dose. People who have taken their initial vaccine dose at least six months prior can take their Pfizer booster dose. Apart from this, there are a few more criteria a person must fulfill to be eligible for the boosters.
Americans are way keener to get their booster shot for extra protection against the contagious Covid-19 virus. Data from the US Centers for Disease Control and Prevention show that about 9 million vaccinated people have already received their booster shots.
The USA Food and Drug Administration’s advisors met on Thursday to discuss the approval of Moderna’s application for the booster shot. The voting by the board went in favor of Moderna’s booster shots of the Covid-19 vaccine to the same group as Pfizer’s.
The rising discussion on the boosters is perhaps distracting the administration from the initial vaccination of the unvaccinated Americans. There are still about 15 states in the nation that have not vaccinated – even 50 percent of their vaccination.